Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

Table 3 Comparison between 4 weeks pre- and 4 weeks post-TMS as regards clinical data of migraine, MIDAS, and serum levels of neurokinin A in group A (migraine without aura)

		Without aura		Test value	P value
		Pre-TMS, no. = 30	Post-TMS, no. = 30	Test value	P value
Neurokinin A serum level	Mean ± SD	24.26 ± 2.38	12.44 ± 2.94	− 4.782^•	< 0.001
Neurokinin A serum level	Range	19.38–27.93	9.32–25.45	− 4.782^•	< 0.001
No. of headache attacks (days per month)	Median (IQR)	17.50 (16.00–25.00)	6.00 (2.00–8.00)	− 4.786^ǂ	< 0.001
No. of headache attacks (days per month)	Range	7.00–27.00	0.00–25.00	− 4.786^ǂ	< 0.001
Duration of individual attack (hours)	Median (IQR)	15.63 (12.75–18.25)	.25 (0.13–0.38)	− 4.762^ǂ	< 0.001
Duration of individual attack (hours)	Range	4.75–42.00	0.00–19.50	− 4.762^ǂ	< 0.001
No. of pills (per month)	Median (IQR)	27.00 (15.00–33.00)	0.00 (0.00–2.00)	− 4.683^ǂ	< 0.001
No. of pills (per month)	Range	0.00–79.00	0.00–33.00	− 4.683^ǂ	< 0.001
Pain intensity	Median (IQR)	7.50 (7.25–7.75)	1.75 (0.75–2.50)	− 4.708^ǂ	< 0.001
Pain intensity	Range	5.25–8.75	0.00–7.75	− 4.708^ǂ	< 0.001
MIDAS score	Median (IQR)	30.50 (23.00–39.00)	2.00 (0.00–5.00)	− 4.783^ǂ	< 0.001
MIDAS score	Range	6.00–57.00	0.00–50.00	− 4.783^ǂ	< 0.001

P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.001, highly significant (HS)
^•Paired t test
^ǂWilcoxon’s rank test